FDA – medicarereport.org

Aging FDA Medicare - General Part D/Prescription Drugs

Science finally figured out how to make effective RSV vaccines. Will seniors care?

May 26, 2023May 26, 2023 Eileen Cook 0 Comments FDA, medicare, Older Adults, RSV, Vaccines

(By Helen Branswell for STAT) The world has waited decades for vaccines to protect older adults against RSV. One, made

Alzheimer's/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

How Medicare’s Aduhelm decision revived old questions about new drugs

May 25, 2023May 25, 2023 Eileen Cook 0 Comments Aduhelm drug, Alzheimer's Disease, Alzheimer's Treatment, CMS, FDA, medicare

(By Kerry Dooley Young for STAT) Medicare’s decision to withhold coverage for Biogen’s Aduhelm despite the Food and Drug Administration’s

Alzheimer's/Dementia FDA Health Care Finance Medicare - General Part D/Prescription Drugs

New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare

May 19, 2023May 19, 2023 Eileen Cook 0 Comments Alzheimer's Disease, FDA, Healthcare Finance, Lecanemab Drug, medicare

(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published May 18, 2023) The FDA’s accelerated approval of Aduhelm

Alzheimer's/Dementia FDA Part D/Prescription Drugs

Eli Lilly says an experimental drug slows Alzheimer’s worsening

May 4, 2023May 4, 2023 Eileen Cook 0 Comments Alzheimer's Disease, Donanemab, Experimental Alzheimer's Drug, FDA

(Source -The Associated Press published May 4, 2023 by NPR) WASHINGTON — Eli Lilly and Co. said Wednesday its experimental

Alzheimer's/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

26 state attorneys general urge Medicare to cover Alzheimer’s treatments

May 3, 2023May 3, 2023 Eileen Cook 0 Comments Alzheimer's Disease, Alzheimer's Treatment, CMS, FDA, medicare

(By Rylee Wilson for Becker’s Hospital Review) Twenty-six state attorneys general are asking Medicare to cover monoclonal antibody treatments for

Abbott glucose monitor readers could catch fire, FDA warns in recall notice

April 7, 2023 Eileen Cook 0 Comments Abbot glucose monitor, FDA, Glucose Monitor, Recall Notice

(By Lizzy Lawrence for STAT) Health care giant Abbott issued a warning impacting four million readers for glucose monitors after

FDA Legislative Update Part D/Prescription Drugs

FDA has new leverage over companies looking for a quicker drug approval

March 3, 2023March 3, 2023 Eileen Cook 0 Comments FDA, FDA’s accelerated approval, Medicare Part D

(By Sydney Lupkin for NPR) The huge spending bill that became law last December also included fixes to a problem

Alzheimer's/Dementia CMS FDA Part D/Prescription Drugs

CMS STATEMENT: Response to Alzheimer’s Association’s Request to Reconsider the Final National Coverage Determination

February 23, 2023February 23, 2023 Eileen Cook 0 Comments Alzheimer's Disease, CMS, FDA, Monoclonal Antibodies, National Coverage Determination

(Source – www.cms.gov) Alzheimer’s disease is a devastating illness that affects millions of Americans and their families. The Centers for

FDA Health Care Finance Part D/Prescription Drugs

A Bitter Battle Over the ‘Orphan Drug’ Program Leaves Patients’ Pocketbooks at Risk

February 22, 2023February 22, 2023 Eileen Cook 0 Comments Court Case, FDA, Healthcare Costs, Medicare Part D, Orphan Drug Program

(By Sarah Jane Tribble for Kaiser Health News) A prescription drug that helps Lore Wilkinson walk and talk despite a

FDA Health Care Finance Part D/Prescription Drugs

AbbVie’s blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

February 1, 2023 Eileen Cook 0 Comments Biosimilars drugs, FDA, Generic Drugs

(Leslie Walker and Dan Gorenstein for NPR) After 20 years and $200 billion in revenue, Humira — an injectable treatment

← Previous